AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01123096 — intervention group
Intervention type: OTHER
Intervention: 24 Hour Pad Test
Description: The patient will be provided with a standard number of pads in a sealed bag that have been pre-weighed. The patient will wear the pads for 24 consecutive hours then return the all the pads within the bag for weighing post usage.
Study NCT03815968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low sodium diet
Description: included in the diet mostly low sodium food. avoid tinned or smoked, food. avoid adding salt to the food.
Study NCT01017419 — intervention group
Intervention type: BEHAVIORAL
Intervention: Counseling
Description: Informational Counseling provided after hearing aid fitting
Study NCT02784678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: closed reduction group
Description: Patients in the experimental group will undergo C-arm fluoroscopy-assisted minimally invasive closed reduction and internal fixation with fully threaded headless cannulated compression screws. In the experimental group, fractures will be reduced and internally fixed with fully threaded headless cannulated compression screws of appropriate lengths (Acutrak plus; Acumed Inc., Beaverton, OR, USA) under C-arm fluoroscopic guidance to restore the radial inclination and ulnar deviation of the distal radius.
Study NCT02784678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: open reduction group
Description: Patients in the control group will undergo open reduction and internal fixation with a titanium plate (Ningbo Cibei Medical Treatment Appliance Co., Ltd., Ningbo, China).
Study NCT01026259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warming of surgical incision
Description: A warming pack (chemical activation) is applied to the dressing over the surgical incision, warming to 38 degrees C, for a period of 90 minutes times 6 treatments. The first treatment occurs in the PACU.
Study NCT00764959 — intervention group
Intervention type: DEVICE
Intervention: Encore Linear™ Hip System
Description: Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis, have received the hip system and are willing to participate in the study.
Study NCT01026259 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warming dressing without actual warming
Description: The same type of surgical incision dressing is used but no warming treatments are administered.
Study NCT02489591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral appliance
Description: Patients will bring their prescribed oral appliance.
Study NCT02489591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BluePro oral appliance
Description: Patients without a prescribed oral appliance will have a device provided for the duration of the study (BluePro, BlueSom; used for investigational purposes only). The device provided is a prefabricated thermoplastic customizable mandibular advancement splint.
Study NCT02331693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-EGFR CAR T
Study NCT02007941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501
Description: From day 1 to day 3, Once(Day1) CKD-501 0.5mg is administered .
Study NCT03864978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04067674 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Blood sampling for biomarker measurement
Study NCT02933606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNC210
Study NCT02933606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01674114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Study NCT01674114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control
Study NCT03254875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individually tailored nurse navigation
Description: The intervention consists of systematic report of symptoms to the nurse and up to six individual, manual-based, face-to-face or telephone nurse navigator sessions depending on individual needs.
Study NCT02027207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shanchol
Description: We will use the killed whole cell oral cholera vaccine, Shanchol that will be manufactured by Shantha Biotechnics, in Hyderabad, India for the study. The vaccine is registered in India and is prequalified by the WHO. Shanchol is available in a single dose vial. Vaccine will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive vaccine.Pregnancy status will be enquired verbally for all married women of child bearing age during the census update as well as before vaccination to exclude them from the study.~Prior to vaccination, informed consent will be taken from the adults and guardians of minor participants .Each dose of vaccine will be 1.5 ml in volume.
Study NCT02027207 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be transported from the manufacturer and will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive placebo.Each dose of placebo will be 1.5 ml in volume.Placebo will be dispensed in liquid form in identical vials.
Study NCT03241875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg
Description: In this group, premedication is performed with 2 capsules of pregabalin 2 hours before anesthetic induction.
Study NCT03241875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 300mg
Description: In this group, premedication is performed with 2 capsules of gabapentin 2 hours before anesthetic induction.
Study NCT03241875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: In this group, no premedication is performed, but patients receive 2 capsules of placebo 2 hours before anesthetic induction.
Study NCT01446315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Asthma APGAR system and tools
Description: Practices will use the Asthma APGAR control questionnaire and the care algorithm.
Study NCT01446315 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Asthma APGAR tools
Description: Usual care
Study NCT01853423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamune
Description: Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
Study NCT04430660 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 13C-MRS procedure/Acetate infusion
Description: Glial metabolism will be measured via MRS utilizing a simultaneous intravenous infusion of 13C labeled acetate. An intravenous catheter will be placed in a vein of each arm, one to infuse 13C-acetate and the other to draw blood samples.
Study NCT00124228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Albumin
Description: albumin 1.5g/kg body weight the first day of inclusion plus 1g/kg/body weight the 3th day of inclusion.
Study NCT04094129 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wismemo
Description: Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-89, Lactobacillus paracasei GMNL-133 and Lactobacillus plantarum GMNL-141.
Study NCT04094129 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04430660 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous glucose monitoring
Description: Participants will wear blinded continuous glucose monitoring devices (dexcom, G6) for approximately 4 weeks. Sensors will be replaced every 7-10 days.
Study NCT04629612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Description: Regional anesthesia such as paravertebral block, pectoral block, superficial cervical plexus block, etc applies according to institution protocol
Study NCT01623531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fibrinogen
Description: Intravenous concentrated fibrinogen will be infused according to a hemostatic algorithm based on ROTEM (FIBTEM)
Study NCT01623531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinogen
Description: Intravenous concentrated fibrinogen will be infused according to a hemostatic algorithm based on ROTEM (FIBTEM)
Study NCT02947516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided liver biopsy
Description: Participants will undergo endoscopic ultrasound per standard technique, with liver biopsy performed at that time.
Study NCT03618849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Real and sham tDCS/Mozart piano sonata (K.448)
Study NCT00932022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trospium Chloride, Extended Release (XR)
Description: Trospium chloride extended release 60 mg capsule taken orally once daily for 12 weeks.
Study NCT00932022 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.
Study NCT00932022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.
Study NCT01125319 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Study NCT03353116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the mandible first
Description: the mandible osteotomy is going to be done and fixed first
Study NCT03353116 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the maxilla first
Description: the maxilla osteotomy is going to be done and fixed first
Study NCT00644709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin tablets at starting doses of 10, 20, 40, or 80 mg once daily. Three dose adjustments were allowed at baseline, Week 17, and Week 34. Patients who did not meet the LDL-C target at any of these time points had their doses doubled except for those who were on the 80 mg dose. Treatment was given for 52 weeks.
Study NCT00732953 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Genous stent implantation with paclitaxel-eluting balloon dilation
Description: Genous stent implantation with paclitaxel-eluting balloon therapy
Study NCT00732953 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Genous stent implantation
Description: Genous stent implantation
Study NCT04531137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CLA-fortified milk powder
Description: 3.4 gram of CLA-fortified milk powder one a day for 12 weeks
Study NCT04531137 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo milk powder one a day for 12 weeks
Study NCT04531137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Counseling
Description: Individualized nutrition counseling using nutrition module at week 0, 4, and 8 for 30-45 minutes each session
Study NCT04531137 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition Counseling
Description: Individualized nutrition counseling using nutrition module at week 0, 4, and 8 for 30-45 minutes each session
Study NCT02631343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KMC
Description: Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
Study NCT02631343 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Essential newborn care
Study NCT03718741 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy +/- CT
Description: Adiuvant Radiotherapy +/- weekly cisplatin
Study NCT04954378 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: radiomics
Study NCT01610609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Population Health Management Intervention
Description: This intervention includes:~* Care manager led patient education to promote increased patient awareness of personal cardiovascular disease (CVD) risk and~* Care manager led patient outreach to facilitate the treatment of eligible and appropriate patients with statins for primary CVD prevention
Study NCT02007941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-501
Description: From day 1 to day 3, Once(Day1) CKD-501 0.5mg is administered .
Study NCT03522402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 38 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to either the patient's head in the neutral position or 30 degree rotated lateral position. The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
Study NCT03522402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: 38 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to either the patient's head in the neutral position or 30 degree rotated lateral position. The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
Study NCT02631343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential newborn care
Study NCT01418391 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane block
Description: TAP BLOCK:~dosage form: 0.5% bupivacaine 75mg with 2% xylocaine 300 mg mixed dosage: total 30 ml frequency: single shot duration: 12\~18 hours upon to the regional anesthetics choose
Study NCT01080872 — intervention group
Intervention type: DEVICE
Intervention: CFR
Description: CFR will be assessed using transthoracic echocardiography with adenosine infusion.
Study NCT05056051 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WATS-3D tissue sampling prior to forceps biopsies
Description: WATS-3D is a brush-based tissue sampling technique. Abrasive brush sampling of large areas of the esophagus pick up cells to obtain trans-epithelial specimens. This technique samples much larger tissue areas than standard forceps biopsies. Analysis is then done by proprietary neural-network based computer scanning and molecular diagnostics to identify abnormal cells.
Study NCT05056051 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WATS-3D tissue sampling following forceps biopsies
Description: WATS-3D is a brush-based tissue sampling technique. Abrasive brush sampling of large areas of the esophagus pick up cells to obtain trans-epithelial specimens. This technique samples much larger tissue areas than standard forceps biopsies. Analysis is then done by proprietary neural-network based computer scanning and molecular diagnostics to identify abnormal cells. This will be done after forceps biopsies in this arm.
Study NCT01587755 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TTOP
Description: Patient is taken care of in an intensified, optimised manner
Study NCT01587755 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: non-TTOP
Description: Standard medical care
Study NCT02886754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proficiency-based progression
Description: Use of validated metrics and performance benchmarks to simulation training
Study NCT02886754 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: National e-learning programme only
Description: National e-learning programme (COMPASS)
Study NCT02886754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: National e-learning programme only
Description: National e-learning programme (COMPASS)
Study NCT02886754 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard simulation
Description: Paper based simulation cases
Study NCT04164680 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multimodal Neuroimaging
Description: fludeoxyglucose (FDG-)PET/MR imaging
Study NCT04276402 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irradiation of implants with 808nm laser
Description: Irradiation of implants with 808nm laser
Study NCT00908817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone acetonide
Description: paste applied over tracheal tube for lubrication
Study NCT00908817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: chlorhexidine gluconate
Description: jelly applied over tracheal tube for lubrication
Study NCT01901276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg bid
Description: As above.
Study NCT00492791 — intervention group
Intervention type: DEVICE
Intervention: wireless endoscopy capsule
Description: Firslty patency ingestion then wireless endoscopy capsule exam done
Study NCT03753841 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adjustment of oral diet
Description: Adjustment of oral diet based on findings in fiberendoscopic evaluation of swallowing (FEES)
Study NCT00662480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Screening for hypertension, lower limb atherosclerosis and abdominal aortic aneurysm
Description: Invited to vascular screening
Study NCT04302844 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Imago Relationship Therapy
Description: Imago relationship therapy (IRT) involves learning the Imago dialogue process, which helps couples understand more clearly why they and their partners react as they do. Couples practice communicating in a manner that helps them move from reactivity and blame to understanding and empathy. The dialogue is used to transform conflicts into opportunities for healing and growth, and to connect more deeply and effectively with one another. Specific topics of therapy are determined by the couple's needs and goals. In general, the therapist helps them use the Imago dialogue to promote understanding, heal painful emotions, and make requests of one another to change behaviors. In effort to minimize risk of exposure to the virus that causes COVID-19, since the spring of 2020, therapy sessions will be conducted via telehealth, with a HIPAA-compliant audio/visual platform, and with couples at home or in another private place during the therapy sessions and the therapist in his or her office.
Study NCT04302844 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist with Bibliotherapy followed by Workshop
Description: Participants assigned to this group will be asked to wait for 12 weeks before receiving any intervention, and will be given a relationship-focused self-help book to read, with exercises to practice, during that time. After 12 weeks and the 12-week assessment has been completed, couples will attend an educational workshop that provides the principles and communication skills of Imago Relationship Therapy, typically in a weekend format that is usually about 18-20 hours. The workshops, called Getting the Love You Want (GTLYW), are led by certified and experienced Imago workshop presenters, and are attended by a group of couples. The workshop includes presentations, discussions, and practice of communication exercises. Participation in the workshops will also be virtual or via telehealth, as described above.
Study NCT01714193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptive
Description: One tablet (0.150 mg of levonorgestrel and 0.030 mg of ethinyl estradiol) taken orally (by mouth) on Day 1 and Day 9.
Study NCT01714193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
Study NCT00355940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technological Methods
Description: Usage of technological methods and devices to improve intravascular navigation during endovascular aortic repair.~In this arm we first use an optical pointer to allocate the femoral artery ramification (point of incision) and the lower renal artery (upper confinement of stent graft). Later we use an electromagnetically tracked catheter to find and enter the opening in the main stent graft before placing the second limb. For both optical and electromagnetic tracking we use a custom made navigation system based on 3 dimensional CT images
Study NCT00355940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular Fluoroscopy
Description: Usage of conventional fluoroscopy and angiography for intravascular navigation. In this arm standard endovascular aortic repair is performed. The only means of navigation are fluoroscopy and angiography with overlay function (standard).
Study NCT02994719 — intervention group
Intervention type: DRUG
Intervention: Anti-Parkinson medication
Description: During the optional second visit subjects with neurological disease and already on anti-parkinson medication are asked to come off their anti-parkinson medication.
Study NCT02994719 — intervention group
Intervention type: DEVICE
Intervention: Deep Brain Stimulation
Description: During the optional second visit subjects with neurological disease already treated with deep brain stimulation are asked to come temporarily stop deep brain stimulation and resume stimulation, with walking trials done in each condition.